Creating Value Through Breakthrough Science

We invest in early & late stage companies taking novel scientific approaches to address significant unmet needs in the life sciences and information technology sectors

More Info
Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52 Ventyx Biosciences announces $27 million strategic investment from Sanofi PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52 Ventyx Biosciences announces $27 million strategic investment from Sanofi PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52 Ventyx Biosciences announces $27 million strategic investment from Sanofi PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52 Ventyx Biosciences announces $27 million strategic investment from Sanofi PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52 Ventyx Biosciences announces $27 million strategic investment from Sanofi PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program

Our Approach

New Science Ventures, LLC (NSV) is a Connecticut and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors

Learn More

News

October 15, 2024
Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative

Read More
September 23, 2024
Ventyx Biosciences announces $27 million strategic investment from Sanofi

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of

Read More
September 10, 2024
PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program

PlanetiQ, a leading innovator of global atmospheric observing systems, has been awarded a Delivery Order (DO-4) contract valued at over $6.5M to supply the National Oceanic and Atmospheric Administration (NOAA) with their proprietary radio occultation (RO) data for a period of one year beginning September 18, 2024. “In addition to

Read More
September 6, 2024
Ventyx Biosciences announces initiation of dosing in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s

Read More
August 5, 2024
Vascular Therapies completes enrollment in the ACCESS 2 study, a Phase III multinational randomized clinical trial of the Sirolimus Eluting Collagen Implant (Sirogen™) for the surgical creation of arteriovenous fistula for hemodialysis vascular access

Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, has announced completion of enrollment in the ACCESS 2 trial, a Phase III prospective randomized, multicenter clinical study of Sirogen™ for the surgical creation of arteriovenous (AV) fistula in patients requiring hemodialysis vascular access.

Read More
July 29, 2024
Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in participants with moderately to severely active Crohn’s disease

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of its allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active

Read More
July 17, 2024
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution

Emporos, the industry’s leading Pharmacy Commerce System including Point of Sale (POS), and InterLink AI, creator of scripClip, a state-of-the-art, lighted pharmacy will-call system, are delighted to announce they have entered a strategic partnership. Pharmacies now have access to a POS-integrated lighted will-call solution for streamlined prescription will-call, checkout, and

Read More
July 9, 2024
Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters

Phase Four, a leading provider of next generation electric propulsion solutions for satellites, proudly announces the signing of a strategic cooperation agreement with Redwire Space (Redwire). This partnership aims to build and deliver Hall Effect Thrusters (HETs) to both government and commercial markets, enhancing the company's capabilities and expanding our

Read More
June 19, 2024
Primemas selects Achronix embedded FPGA technology for System-on-Chip (SoC) Hub Chiplet platform

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Primemas, a fabless semiconductor company developing an innovative SoC Hub Chiplet (Hublet) platform using chiplet technology, has announced a collaboration to bring FPGA programmability to the Primemas suite of products. Primemas chose the Speedcore™ eFPGA IP

Read More
June 5, 2024
Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models. “We are excited by these

Read More
May 13, 2024
Resolve Therapeutics publishes results of RSLV-132 Phase 2 long COVID study

Resolve Therapeutics, a mid-stage clinical development company pioneering transformative therapies for autoimmune and post-viral illnesses, has announced the publication of its Phase 2 long COVID results in Clinical Infectious Diseases. The publication entitled “Assessment of the Impact of RNase in Patients with Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2

Read More
April 9, 2024
Finally, Graphene electronic devices available for all

Paragraf, the world’s only mass producer of graphene electronics using transfer-free graphene grown with conventional semiconductor processes, has opened a new online store to enable global access to its unique Graphene-based Field Effect Transistor (“GFET”). GFETs have a wide range of uses in the development of industry, medical, and chemical

Read More
April 4, 2024
DARPA awards Phase Four $14.9M contract to develop Air Breathing Electric Propulsion for Very Low Earth Orbit operations

Phase Four, a leading provider of next generation electric propulsion (EP) solutions for satellites, has been awarded a $14.9M contract by the Defense Advanced Research Projects Agency (DARPA) to deliver an "air-breathing" EP system to enable extended satellite operations in Very Low Earth Orbit (VLEO), at altitudes as low as

Read More
March 26, 2024
Achronix FPGAs add support for Bluespec’s Linux-capable RISC-V Soft Processors to enable scalable processing

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Bluespec, Inc., an industry leader in RISC-V tools and silicon IP, has announced a family of Linux-capable RISC-V soft processors that are available for the Achronix Speedster®7t FPGA family. Marking an industry first, Bluespec’s RISC-V processors

Read More
March 11, 2024
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, have provided clinical and pipeline updates during its virtual investor event. “We are excited to announce clinical updates from our novel

Read More
February 21, 2024
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-associated metabolic diseases, has announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD),

Read More
February 12, 2024
Resolve Therapeutics announces publication of Lupus clinical trial results

Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, has announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine. The publication entitled "Evaluation of RNase therapy in systemic lupus

Read More
February 5, 2024
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC

Novel solution distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) revealing unprecedented insights into current and future states of disease using one 5ng DNA sample biomodal, an omics-based life sciences technology and analytics company, has announced it’s delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet

Read More
December 21, 2023
InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip

The European Investment Bank (EIB) and Novadip have signed a €18 million venture debt financing agreement supported by the European Union’s InvestEU initiative. The Belgian biotech company will use the funds to support clinical trials of NVD-003, an autologous bone product that provides one-time curative treatment to achieve long-term union

Read More
December 14, 2023
Repeated Signal Solutions, Inc. and Avari Wireless Inc. announce Enhanced ERCES Monitoring

Repeated Signal Solutions, Inc. (RSS) and Avari Wireless Inc. have announced the launch of Enhanced ERCES Monitoring™.  Enhanced ERCES Monitoring™ is a new service that allows building owners to monitor their First Responder (ERCES) radio systems remotely with the same level of visibility as required by the NFPA code. "Enhanced

Read More
Previous Next

Our Companies

We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value

Learn More

Our Team

The team brings a wealth of investment experience and board expertise in the life sciences and information technology sectors across US and Europe

Learn More

Contact Us

Greenwich

500 West Putnam Avenue, Suite 400, Greenwich CT 06830
T: 212 688 5100 F: 646 844 9845

London

Michelin House, 81 Fulham Road, London SW3 6RD
T: 020 3981 9092